Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PBYI
Strong BuyFLAGPuma Biotechnology, Inc. · Healthcare · United States · $468M · Avg Vol: $3M/d
Puma Biotechnology depends almost entirely on a single marketed breast-cancer drug whose revenue has been in decline against newer competing agents, which the trailing quality score does not capture. There is modest insider selling and no supportive evidence. No fraud, restatement or distress event is known, so this is a flag rather than a removal.
COMPANY DESCRIPTION
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of cancer. Its lead product, Nerlynx, is approved for certain types of early-stage HER2-positive breast cancer. The company's competitive position is anchored by its approved oncology therapeutic and ongoing clinical development pipeline, operating in the high-stakes pharmaceutical market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 228.0M | 235.6M | 230.5M | 228.4M | 0.0% | 231.2M |
| EPS | 0.00 | 0.46 | 0.62 | 0.62 | 16.1% | 0.51 |
| Shares | 46.3M | 47.6M | 49.1M | 50.4M | +8.8% | 51.6M |
| Debt | 114.3M | 111.5M | 74.1M | 28.5M | -37.0% | 4.8M |
| Equity | 21.6M | 53.4M | 92.1M | 130.3M | 82.0% | — |
| Op CF | -15.8M | 27.0M | 38.9M | 41.8M | 24.4% | 41.1M |
| Inv CF | 7.1M | -19.1M | -20.4M | -36.2M | — | — |
| Fin CF | 12.2M | 0 | -33.8M | -45.2M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBYI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBYI | Puma Biotechnology, Inc.(you) | $468M | 99 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 88 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $310M | 92 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 97 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 87 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 84 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.7%